Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated assessment is fully supported by the provided label excerpts (Warnings/Precautions) for rare but serious renal failure/acute phosphate nephropathy after oral sodium phosphate colon cleansing, including the specified increased-risk factors and concomitant medications.
Category Scores
Accurate Statements
There have been rare, but serious reports of renal failure, acute phosphate nephropathy, and nephrocalcinosis in patients who received oral sodium phosphate products (including oral sodium phosphate solutions and tablets) for colon cleansing prior to colonoscopy.
WARNINGS (Section 5) excerpt: rare but serious reports; includes oral sodium phosphate tablets for colon cleansing prior to colonoscopy; includes renal failure, acute phosphate nephropathy, nephrocalcinosis.
The time to onset is typically within days; however, in some cases, the diagnosis has been delayed up to several months after ingestion.
WARNINGS (Section 5) excerpt: onset typically within days; delayed diagnosis up to several months.
Patients at increased risk may include those with hypovolemia, baseline kidney disease, increased age, and patients using medicines that affect renal perfusion or function (such as diuretics, ACE inhibitors, angiotensin receptor blockers, and possibly NSAIDs).
WARNINGS (Section 5) excerpt: enumerated increased-risk factors and examples of concomitant medication classes.
Postmarketing renal adverse events identified include renal impairment, increased BUN, increased creatinine, acute renal failure, acute phosphate nephropathy, nephrocalcinosis, and renal tubular necrosis.
WARNINGS/ADVERSE REACTIONS post-approval experience excerpts provided (renal adverse events list includes acute renal failure and acute phosphate nephropathy).
Inadequate fluid intake may lead to excessive fluid loss, hypovolemia, and dehydration; dehydration may be exacerbated by inadequate oral fluid intake, vomiting, and/or use of diuretics.
PRECAUTIONS (provided under Section 5 in the prompt): inadequate fluid intake → fluid loss/hypovolemia/dehydration; exacerbated by vomiting and/or diuretics.
Unsupported Statements
Contradictions
Important Omissions
The AI assessment does not explicitly mention the contraindications (biopsy-proven acute phosphate nephropathy; hypersensitivity) or the broader list of conditions advised for considerable caution (e.g., severe renal insufficiency with specific creatinine clearance threshold, congestive heart failure, ascites, bowel obstruction, etc.).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims accurately restate on-label renal risk and identified higher-risk factors; no contradictory or unsupported risk assertions were made.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omitted additional on-label caution/contraindication details not necessary for the narrow renal-risk claim but present in the label.
Suggested Improvement
If presenting a broader safety summary, include the contraindications and the full list of conditions for considerable caution and/or electrolyte correction and hydration guidance from the label.